Enlivex Therapeutics Ltd. (NASDAQ:ENLV) to Post Q2 2024 Earnings of ($0.22) Per Share, HC Wainwright Forecasts

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Research analysts at HC Wainwright upped their Q2 2024 EPS estimates for shares of Enlivex Therapeutics in a research report issued on Tuesday, June 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.22) for the quarter, up from their previous estimate of ($0.24). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q3 2024 earnings at ($0.18) EPS, Q4 2024 earnings at ($0.18) EPS, FY2024 earnings at ($0.81) EPS and FY2025 earnings at ($0.59) EPS.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings results on Friday, March 29th. The company reported ($0.48) earnings per share for the quarter.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ ENLV opened at $1.44 on Thursday. Enlivex Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $4.59. The stock has a market cap of $30.05 million, a price-to-earnings ratio of -0.92 and a beta of 1.26. The firm’s 50-day simple moving average is $1.61 and its 200 day simple moving average is $2.49.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.